VERICI DX PLC (VRCI) — Investor Presentation

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the VERICI DX PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and will be submitted at any time by the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and will publish those responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to the management team. Sarah, good afternoon. Thank you very much. Welcome everybody. I'm I'm going to just flip over the first couple of slides given that they are the disclaimer slides and not sure how how much everybody's going to be able to read those on the fly. But just a reminder of the company's products here, we have a suite of three blood based tests and they are all addressed for kidney transplant patients. It's based on the technology of RNA sequencing with an AI algorithm attached. And just as a reminder to everybody, what is RNA? RNA is like the messaging of the body. So it enables clinicians to pick up signals at a very early stage. We call this an early biomarker and make a distinction between this and the competitive technology of cell free DNA which is effectively a late biomarker. It's an injury marker. It picks up the debris in the blood. So this is something that is enabling us to to to effectively have a very proactive messaging signaling system of the body. We have three products and if we think about them in terms of order in the patient journey, the first one was a pre transplant test. Effectively, the RNA signatur...